Articles: PDF OnlyNovel Pharmacotherapy Strategies for Mood Disorders: Part IIDike, Charles MRCPsych, MD; Janicak, Philip G. MD Author Information CME article by Charles Dike, MRCPsych, MD, Fellow in the Law and Psychiatry Division, Department of Psychiatry, Yale University School of Medicine; and Philip G. Janicak, MD, Professor of Psychiatry and Pharmacology, Pharmacology, University of Illinois at Chicago Dr. Dike has disclosed that he has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. Dr. Janicak has disclosed that he receives grant/research support from Janssen, Bristol- Myers Squibb, Genentech, and the NIH; is a consultant for Janssen, Pfizer, Bristol-Myers Squibb, and Sepracor; and is on the speakers' bureau for Abbott, Janssen, Bristol-Myers Squibb, Pfizer, Astra Zeneca, Forest, and Eli Lilly. The authors have further disclosed that except for olanzapine, none of the antipsychotics mentioned in this article has been approved by the U.S. Food and Drug Administration for the treatment of mood disorders. International Drug Therapy Newsletter: October 2002 - Volume 37 - Issue 10 - p 73-76 Buy Abstract Learning Objectives: After reading this article, the practitioner should be able to: Review the role of the glutamate/N-methyl-D-aspartate system in depression. Discuss potentially effective formulations of estrogens for the treatment of depression. Discuss the role of pharmacogenetics in the drug treatment of depression. © 2002 Lippincott Williams & Wilkins, Inc.